Holen Sie sich die Stockscreener-App
15.49
5.28%
0.7998
Schlusskurs vom Vortag:
$14.69
Offen:
$14.72
24-Stunden-Volumen:
1.54M
Relative Volume:
0.90
Marktkapitalisierung:
$4.94B
Einnahmen:
$3.05B
Nettoeinkommen (Verlust:
$181.32M
KGV:
41.45
EPS:
0.3737
Netto-Cashflow:
$225.64M
1W Leistung:
+20.12%
1M Leistung:
+17.16%
6M Leistung:
+26.66%
1J Leistung:
+98.02%
1-Tages-Spanne:
$14.65
$15.64
1-Wochen-Bereich:
$13.00
$15.64
52-Wochen-Spanne:
$7.665
$15.64
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
15.49 | 4.69B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
15.79 | 49.67B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.155 | 40.26B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.01 | 40.11B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
82.60 | 34.46B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
546.36 | 23.48B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | UBS | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals - marketscreener.com
Why Amneal (AMRX) stock is trading up today - MSN
AMRX: Biosimilars, specialty launches, and strategic partnerships drive robust long-term growth - TradingView
Amneal Pharmaceuticals, Inc. (AMRX) Latest Stock News & Headlines - Yahoo Finance
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase - Yahoo Finance
Amneal and Pfizer GLP-1 Deal: New Growth Lever? - Yahoo Finance
Is Amneal a Buy Before Rytary Generic Erosion? - Yahoo Finance
What's Driving Amneal's 2026 Growth Outlook? - TradingView
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution - Pharmacy Practice News
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data - Sahm
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations - Yahoo Finance
Amneal reports interim data on Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa
Amneal reports interim data for Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution - The Globe and Mail
Amneal reports interim data on Parkinson’s drug CREXONT - Investing.com UK
Amneal Pharmaceuticals Reports Positive Interim Data from Phase 4 ELEVATE-PD Study Demonstrating Benefits of CREXONT in Parkinson's Disease Patients - Quiver Quantitative
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease - The Manila Times
Parkinson’s study: CREXONT adds over 3 hours of daily 'Good On' time - Stock Titan
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
AMRX News | AMNEAL PHARMACEUTICALS INC (NASDAQ:AMRX) - ChartMill
Amneal Stock Up on FDA Approval of Romidepsin Injection for Lymphoma PatientsNews and Statistics - IndexBox
Why Amneal (AMRX) Stock Is Trading Up Today - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution - Proactive financial news
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
Amneal Pharmaceuticals Advances After Securing FDA Clearance for Cancer Treatment (AMRX) - Yahoo Finance
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug - Investing.com
FDA approves ready-to-use lymphoma drug, Amneal gains 180 days of exclusivity - Stock Titan
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? - Yahoo! Finance Canada
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Amneal CEO to present at Goldman Sachs 2026 Global Healthcare Conference in June - Pluang
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains - Sahm
Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now? - The Globe and Mail
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):